{"publication":"Heffron (2003)","year":2003,"randomized":"yes","control.type":"concurrent","comparison":"delayed CNI","IL2RA":"daclizumab","CNI":"tacrolimus","MMF":"yes","followup":24,"exp.AR.events":14,"exp.SRR.events":2,"exp.deaths":4,"exp.total":61,"cont.AR.events":15,"cont.SRR.events":4,"cont.deaths":3,"cont.total":20}
{"publication":"Gibelli (2004)","year":2004,"randomized":"no","control.type":"historical","comparison":"IL-2RA only","IL2RA":"basiliximab","CNI":"cyclosporine A","MMF":"no","followup":6,"exp.AR.events":16,"exp.total":28,"cont.AR.events":19,"cont.total":28}
{"publication":"Schuller (2005)","year":2005,"randomized":"no","control.type":"concurrent","comparison":"IL-2RA only","IL2RA":"daclizumab","CNI":"tacrolimus","MMF":"yes","followup":6,"exp.AR.events":3,"exp.PTLD.events":0,"exp.total":18,"cont.AR.events":8,"cont.PTLD.events":0,"cont.total":12}
{"publication":"Ganschow (2005)","year":2005,"randomized":"no","control.type":"historical","comparison":"IL-2RA only","IL2RA":"basiliximab","CNI":"cyclosporine A","MMF":"no","followup":36,"exp.AR.events":9,"exp.SRR.events":4,"exp.PTLD.events":1,"exp.deaths":1,"exp.total":54,"cont.AR.events":29,"cont.SRR.events":6,"cont.PTLD.events":0,"cont.deaths":3,"cont.total":54}
{"publication":"Spada (2006)","year":2006,"randomized":"yes","control.type":"concurrent","comparison":"no/low steroids","IL2RA":"basiliximab","CNI":"tacrolimus","MMF":"no","followup":12,"exp.AR.events":4,"exp.PTLD.events":1,"exp.deaths":4,"exp.total":36,"cont.AR.events":11,"cont.PTLD.events":1,"cont.deaths":3,"cont.total":36}
{"publication":"Gras (2008)","year":2008,"randomized":"no","control.type":"historical","comparison":"no/low steroids","IL2RA":"basiliximab","CNI":"tacrolimus","MMF":"no","followup":36,"exp.AR.events":0,"exp.SRR.events":1,"exp.deaths":2,"exp.total":50,"cont.AR.events":3,"cont.SRR.events":4,"cont.deaths":3,"cont.total":34}